In last trading session, AbCellera Biologics Inc (NASDAQ:ABCL) saw 5.55 million shares changing hands with its beta currently measuring 0.42. Company’s recent per share price level of $3.47 trading at $0.04 or 1.17% at ring of the bell on the day assigns it a market valuation of $1.02B. That closing price of ABCL’s stock is at a discount of -57.06% from its 52-week high price of $5.45 and is indicating a premium of 32.56% from its 52-week low price of $2.34.
For AbCellera Biologics Inc (ABCL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.22. Splitting up the data highlights that, out of 9 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.15 in the current quarter.
AbCellera Biologics Inc (NASDAQ:ABCL) trade information
Upright in the green during last session for gaining 1.17%, in the last five days ABCL remained trading in the green while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $3.47 price level, adding 3.61% to its value on the day. AbCellera Biologics Inc’s shares saw a change of 18.43% in year-to-date performance and have moved 17.63% in past 5-day. AbCellera Biologics Inc (NASDAQ:ABCL) showed a performance of 16.84% in past 30-days.
Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 30.6% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -44.09% in reaching the projected high whereas dropping to the targeted low would mean a loss of -44.09% for stock’s current value.
AbCellera Biologics Inc (ABCL) estimates and forecasts
This year revenue growth is estimated to fall -16.95% from the last financial year’s standing.
10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 7.58M for the same. And 2 analysts are in estimates of company making revenue of 13.97M in the next quarter. Company posted 9.2M and 9.95M of sales in current and next quarters respectively a year earlier.
In 2025, company’s earnings growth rate is likely to be around -15.13% while estimates for its earnings growth in next 5 years are of 1.59%.
AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders
BAKER BROS. ADVISORS LP is the top institutional holder at ABCL for having 27.53 million shares of worth $81.48 million. And as of 2024-06-30, it was holding 9.3556 of the company’s outstanding shares.
The second largest institutional holder is BAILLIE GIFFORD & CO, which was holding about 21.91 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.4472 of outstanding shares, having a total worth of $64.86 million.
